Societal return on investment may greatly exceed financial return on investment in neurotechnology-based therapies: A case study in epilepsy therapy development

CONCLUSION: Despite the immense costs required to develop, test, and commercialize such a system, the direct and indirect economic costs imposed by uncontrolled seizures are sufficiently staggering that a sROI becomes positive after only 400 patients have been successfully treated and returned to work.PMID:34084608 | PMC:PMC8168695 | DOI:10.25259/SNI_230_2020
Source: Surgical Neurology International - Category: Neurosurgery Authors: Source Type: research